本研究对两个队列（西班牙和德国）人类免疫缺陷病毒（HIV）相关伯基特淋巴瘤（BLL）患者，应用密集免疫化学疗法治疗的结果进行了分析。结果显示，80%的患者获得缓解，11%的患者在诱导过程中死亡，9%的患者失败以及7%的患者在缓解期死亡。4年总生存（OS）率和无进展生存（PFS）率分别为72%（95%可信区间[CI]：62-82%）和71%（95%CI：61-81%）。CD4T细胞计数/μL和骨髓累及的患者OS（风险比分别为[HR]3.2[1.2-8.3]和2.7[1.1-6.6]，PFS：HR3.5[1.3-9.1]和HR2.4[1-5.7]）为差。骨髓累及的患者无病生存为差（HR：14.4[1.7-.7]且东部肿瘤协作组评分2，比值比[OR]11.9[1.4-99.9]）。研究表明，对于HIV相关BLL患者而言，密集的免疫化学疗法可行且有效，但存在毒性反应。体力状态、CD4T细胞计数和骨髓累及是预后因素。
该研究正式发表于年10月《白血病淋巴瘤》上（LeukLymphoma.Oct;55(10):-8）。
Dose-intensivechemotherapyincludingrituximabishighlyeffectivebuttoxicinhumanimmunodeficiencyvirus-infectedpatientswithBurkittlymphoma/leukemia:parallelstudyof81patients.
LeukLymphoma.Oct;55(10):-8.doi:10./...EpubFeb25.
XicoyB(1),RiberaJM,MüllerM,GarcíaO,HoffmannC,OriolA,
AbstractTheresultsofintensiveimmunochemotherapywereanalyzedinhumanimmunodeficiencyvirus(HIV)-relatedBurkittlymphoma/leukemia(BLL)intwocohorts(SpainandGermany).Alternatingcyclesofchemotherapywereadministered,withdosereductionsforpatientsover55years.Eightypercentofpatientsachievedremission,11%diedduringinduction,9%failedand7%diedinremission.Four-yearoverallsurvival(OS)andprogression-freesurvival(PFS)probabilitieswere72%(95%confidenceinterval[CI]:62-82%)and71%(95%CI:61-81%).CD4T-cellcount/μLandbonemarrowinvolvementwereassociatedwithpoorOS(hazardratio[HR]3.2[1.2-8.3]andHR2.7[1.1-6.6])andPFS(HR3.5[1.3-9.1]andHR2.4[1-5.7]),bonemarrowinvolvementwithpoordisease-freesurvival(DFS)(HR14.4[1.7-.7]andEasternCooperativeOncologyGroup(ECOG)score2(oddsratio[OR]11.9[1.4-99.9])withinductiondeath.InHIV-relatedBLL,intensiveimmunochemotherapywasfeasibleandeffective,buttoxic.Prognosticfactorswereperformancestatus,CD4T-cellcountandbonemarrowinvolvement.
PMID:
哪儿治疗白癜风好头部白癜风和白癜风的区别
